Welcome
Support Centre
11 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
A randomized trial comparing cyclosporine versus azathioprine for maintenance therapy in diffuse lupus nephritis
ISRCTN ISRCTN34265870
ClinicalTrials.gov identifier
Public title A randomized trial comparing cyclosporine versus azathioprine for maintenance therapy in diffuse lupus nephritis
Scientific title
Acronym N/A
Serial number at source NEO-I-22
Study hypothesis Not provided at time of registration
Lay summary
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment Italy
Disease/condition/study domain Lupus nephritis
Participants - inclusion criteria Seventy five patients presenting with diffuse proliferative lupus nephritis
Participants - exclusion criteria Not provided at time of registration
Anticipated start date 01/01/2000
Anticipated end date 31/12/2004
Status of trial Completed
Patient information material
Target number of participants 75
Interventions Administration of 3 intravenous methylprednisolone pulses followed by a 2-3 month treatment with prednisone and oral cyclophosphamide. Patients with serum creatinine ≤1.5 mg/dl, proteinuria ≥0.5 g per day and diastolic blood pressure <90 mmHg were then randomized to receive cyclosporine or azathioprine for two years.
Primary outcome measure(s) Not provided at time of registration
Secondary outcome measure(s) Not provided at time of registration
Sources of funding The study was sponsored by Novartis and monitored by an external society. The steering committee approved the study protocol, case report forms, statistical analysis plan, progress of the study and analysis, as well as the reporting of the data, whatever the outcome of the study. The sponsors could comment on the manuscript before submission, but the final version was the sole responsibility of the authors. In addition, the steering committee had full access to the data files of the study.
Trial website
Publications 2006 results on http://www.ncbi.nlm.nih.gov/pubmed/17699309
Contact name Prof  Claudio  Ponticelli
  Address via Ampere 126
  City/town Milano
  Zip/Postcode 20131
  Country Italy
Sponsor Novartis Farma (Italy)
  Address Largo U. Boccioni 1
  City/town Origgio
  Zip/Postcode 21040
  Country Italy
  Tel +39 (0)2 9654 2351
  Fax +39 (0)2 9654 2318
  Email simona.greco@pharma.novartis.com
  Sponsor website: http://www.novartis.com/
Date applied 07/07/2004
Last edited 11/02/2008
Date ISRCTN assigned 22/11/2004
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central